$41.01 Million in Sales Expected for Amicus Therapeutics, Inc. (NASDAQ:FOLD) This Quarter

Wall Street brokerages predict that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will post $41.01 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Amicus Therapeutics’ earnings, with estimates ranging from $40.48 million to $42.03 million. Amicus Therapeutics reported sales of $21.31 million in the same quarter last year, which would suggest a positive year over year growth rate of 92.4%. The company is expected to report its next earnings report on Tuesday, August 6th.

On average, analysts expect that Amicus Therapeutics will report full-year sales of $170.00 million for the current financial year, with estimates ranging from $168.51 million to $171.55 million. For the next financial year, analysts anticipate that the business will post sales of $251.00 million, with estimates ranging from $215.12 million to $266.68 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.09). Amicus Therapeutics had a negative return on equity of 64.11% and a negative net margin of 386.18%. The company had revenue of $34.00 million during the quarter, compared to analyst estimates of $37.82 million. The business’s quarterly revenue was up 103.6% on a year-over-year basis.



Several research firms recently weighed in on FOLD. BidaskClub upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. ValuEngine upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Janney Montgomery Scott began coverage on Amicus Therapeutics in a report on Friday, April 5th. They issued a “buy” rating and a $13.91 target price for the company. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Finally, Cantor Fitzgerald set a $20.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 8th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $18.06.

FOLD traded down $0.31 on Friday, hitting $11.35. The company had a trading volume of 1,807,226 shares, compared to its average volume of 2,990,235. Amicus Therapeutics has a 1-year low of $8.27 and a 1-year high of $17.62. The company has a debt-to-equity ratio of 0.45, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market cap of $2.62 billion, a P/E ratio of -8.53 and a beta of 1.87.

In other news, Director Michael Raab sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $11.16, for a total transaction of $55,800.00. Following the completion of the transaction, the director now directly owns 13,895 shares in the company, valued at $155,068.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $13.63, for a total value of $272,600.00. Following the transaction, the chief executive officer now owns 678,290 shares of the company’s stock, valued at $9,245,092.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 115,000 shares of company stock valued at $1,531,600. Corporate insiders own 2.90% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Bank of Montreal Can grew its position in shares of Amicus Therapeutics by 117.9% in the fourth quarter. Bank of Montreal Can now owns 3,428 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,855 shares during the period. Strs Ohio grew its position in Amicus Therapeutics by 56.0% during the 4th quarter. Strs Ohio now owns 3,900 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 1,400 shares during the last quarter. Xact Kapitalforvaltning AB grew its position in Amicus Therapeutics by 15.7% during the 4th quarter. Xact Kapitalforvaltning AB now owns 33,841 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 4,600 shares during the last quarter. Rhumbline Advisers grew its position in Amicus Therapeutics by 48.0% during the 4th quarter. Rhumbline Advisers now owns 252,354 shares of the biopharmaceutical company’s stock worth $2,418,000 after acquiring an additional 81,792 shares during the last quarter. Finally, Meridian Wealth Management LLC grew its position in Amicus Therapeutics by 54.3% during the 4th quarter. Meridian Wealth Management LLC now owns 23,151 shares of the biopharmaceutical company’s stock worth $222,000 after acquiring an additional 8,151 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Recommended Story: Golden Cross

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.